Shinyaku
RegenXBio Secures $110M Upfront in Strategic Partnership with Nippon Shinyaku for Hunter Syndrome Gene Therapy
RegenXBio, Hunter syndrome, Gene therapy, Nippon Shinyaku, Strategic partnership, Rare metabolic disorder, Mucopolysaccharidosis type II (MPS II), RGX-121, RGX-111